Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

After a conference lacking the wow factor, biotech winners and losers emerge.

Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.